Achira AI

Achira AI is a pioneering company focused on transforming drug discovery through advanced simulation models that integrate geometric deep learning, quantum chemistry, and statistical mechanics. Achira AI was founded in 2024 in Greece and specializes in developing simulation models for drug discovery. The company has completed one deal to date, with its most recent funding round in February 2025. Achira AI raised EUR 31.

54 mn in Seed funding, led by Dimension and included investors such as Amplify, Compound, Nventures, and NVidia. Achira AI was founded by a team of experts with previous experience in the biotech sector. Achira offers advanced simulation models designed to revolutionize drug discovery through a unique integration of geometric deep learning, physics, quantum chemistry, and statistical mechanics. The company’s core product focuses on creating atomistic foundation simulation models that deliver high-performance outcomes across a variety of biomolecular applications.

These models are engineered to generate large, accurate synthetic datasets, facilitating a transformative approach to discovering therapeutic compounds. Achira targets pharmaceutical companies, research institutions, and drug discovery scientists, supporting their efforts in harnessing computational methodologies in major pharmaceutical hubs globally, including North America, Europe, and Asia. Achira's revenue model is structured around partnerships and collaborations with pharmaceutical companies and research organizations, facilitating access to its simulation models. Clients engage with Achira through subscription-based access or bespoke arrangements tailored to specific research needs, involving licensing agreements that allow the use of Achira's advanced models for drug discovery.

The focus on large-scale synthetic dataset generation and advanced modeling suggests a premium positioning in the market, reflecting the value and specificity of the services provided. In February 2025, Achira AI raised EUR 31. 54 mn in Seed funding to enhance its AI-driven simulation models and expand its team of computational biologists, theoretical chemists, biophysicists, and chemical engineers. The company plans to introduce new products aimed at improving drug discovery methodologies and is targeting expansion into new markets in North America and Asia by the end of 2026.